AstraZeneca Pharma India Reports Strong Q1 FY27 Growth, Expands Strategic Initiatives
"AstraZeneca Pharma India reported strong Q1 FY27 growth, supported by broad-based performance across its key therapy areas."
AstraZeneca Pharma India Posts Strong Q1 Growth, Backed by Therapy Momentum
AstraZeneca Pharma India Limited reported its financial results for the quarter ended June 30, 2026, with revenue growth supported by continued momentum across its core therapy areas. The company also made progress on new product approvals and healthcare initiatives during the quarter.
Q1 Financial Performance and Key Developments
- Revenue: Rose 30% YoY to Rs 682.8 crore.
- Profit: PBT stood at Rs 51 crore, while PAT reached Rs 50.7 crore.
- Therapy Growth: Oncology grew 26%, Biopharmaceuticals grew 36%, and Rare Diseases grew 35-fold.
- Approvals: Acalabrutinib and trastuzumab deruxtecan received key regulatory approvals.
- Healthcare Initiatives: Launched AI-based lung cancer screening with Telangana and K+ Connect for hyperkalaemia management.
- Cardiovascular Care: Introduced ICC 2026 with STEMI India to strengthen cardiovascular care.
What to Watch Next
Investors will track the contribution of newly approved therapies, continued growth across AstraZeneca's key therapy areas and the impact of its healthcare initiatives on the company's future performance.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Adani Group Stocks in Focus After US Court Dismisses Criminal Charges
Adani Group stocks are set to remain in focus on August 11 after a US federal court dismissed the criminal charges against Gautam Adani, Sagar Adani and former Adani Green CEO Vneet Jaain with prejudice. The ruling brings the criminal proceedings to a close, while a separate civil case filed by the SEC has been resolved through a final judgment.
Sayaji Industries Q1 FY27 Results: EBITDA Surges 287%, Company Returns to Profit
Sayaji Industries Limited presented its investor presentation for the quarter ended June 30, 2026, highlighting improved financial performance in Q1 FY27. Revenue from operations increased 6% year-on-year, EBITDA increased 287% year-on-year to Rs.21 crore, compared with Rs.5 crore in Q1 FY26. The company also provided an update on its technology modernisation and automation project and upcoming joint venture capital expenditure projects.
South India Paper Mills Stake Rises to 18.46% Through Multiple Open-Market Acquisitions
Kirit Natwarlal Modi and Persons Acting in Concert (PAC) have increased their collective shareholding in South India Paper Mills Ltd. through a series of open-market acquisitions. Their combined holding increased from 5.99% to 18.46%, with the final acquisition taking place on March 2, 2026.